Abstract
Objective This study was aimed at investigating the relationship between serum amyloid A (SAA) levels and cognitive dysfunction in patients with vascular dementia (VAD). Methods Using cross-sectional research methods, 146 patients with VAD were selected as the VAD group and 70 normal people were selected as the NC group. Upon admission, the clinical and biochemical characteristics of the two groups of study subjects were collected, and the MMSE scale was used to assess cognitive function. A sandwich enzyme-linked immunosorbent assay was used to detect SAA levels. Results There was no significant difference in clinical data and biochemical characteristics in the VAD group (p > 0.05). Compared with the VAD group, the NC group has a higher level of education (p < 0.05). The SAA level of the VAD group was higher than that of the NC group, and there was a significant difference (p < 0.05). Spearman correlation analysis showed that SAA and MMSE in the VAD group were negatively correlated. Further multiple regression analysis showed that the serum amyloid A level is an independent risk factor for cognitive dysfunction in VAD patients. Conclusion The level of SAA in VAD patients is significantly increased, which can be used as a potential peripheral blood marker to predict cognitive impairment in VAD patients.
Highlights
Vascular dementia (VAD) refers to a syndrome with a clinical stroke or subclinical cerebrovascular injury that affects at least one cognitive dysfunction
Gender, smoke and drinking habits, chronic medical history (HBP, DM, and HLP), and biochemical characteristics (BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP),total cholesterol (TC), TG, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), BUA, serum creatinine (Scr), and aminotransferase/alanine aminotransferase (AST/ALT)), no significant difference was found between the VAD group and the NC group (p > 0:05)
In the early 1990s, the diagnostic criteria for VAD were mainly based on AD, emphasizing irreversible cognitive dysfunction and impaired ability of daily living [13]
Summary
This study was aimed at investigating the relationship between serum amyloid A (SAA) levels and cognitive dysfunction in patients with vascular dementia (VAD). Using cross-sectional research methods, 146 patients with VAD were selected as the VAD group and 70 normal people were selected as the NC group. The clinical and biochemical characteristics of the two groups of study subjects were collected, and the MMSE scale was used to assess cognitive function. There was no significant difference in clinical data and biochemical characteristics in the VAD group (p > 0:05). The SAA level of the VAD group was higher than that of the NC group, and there was a significant difference (p < 0:05). Further multiple regression analysis showed that the serum amyloid A level is an independent risk factor for cognitive dysfunction in VAD patients. The level of SAA in VAD patients is significantly increased, which can be used as a potential peripheral blood marker to predict cognitive impairment in VAD patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
